Noninferiority on overall survival of every-2-weeks vs weekly schedule of cetuximab for first-line treatment of RAS wild-type metastatic colorectal cancer

被引：0
|
作者：
Kasper, S. [1 ]
Cheng, A-L. [2 ]
Overkamp, F. [3 ]
Rouyer, M. [4 ]
Foch, C. [5 ]
Lamy, F-X. [6 ]
Esser, R. [5 ]
Messinger, D. [7 ]
Rothe, V. [7 ]
Chen, W. [8 ]
Brodowicz, T. [9 ]
Zielinski, C. C. [10 ,11 ]
机构：
[1] Univ Hosp Essen, Westdeutsch Tumorzentrum, Med Oncol, Essen, Germany
[2] Natl Taiwan Univ, Ctr Canc, Dept Internal Med & Oncol, Taipei, Taiwan
[3] Oncologianova GmbH, Oncol, Recklinghausen, Germany
[4] Univ Bordeaux, Bordeaux PharmacoEpi, INSERM, CIC1401, Bordeaux, France
[5] Merck Healthcare KGaA, Oncol, Darmstadt, Germany
[6] Merck Healthcare KGaA, Global Epidemiol, Darmstadt, Germany
[7] Prometris GmbH, Biostat, Mannheim, Germany
[8] Merck Serono, Biostat, Shanghai, Peoples R China
[9] Med Univ Vienna, Gen Hosp, Internal Med 1, Dept Med Oncol, Vienna, Austria
[10] Vienna Gen Hosp, Ctr Comprehens Canc, Oncol, Vienna, Austria
[11] Med Univ Vienna, Vienna, Austria
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
584P
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Noninferiority on Overall Survival of Every-2-Weeks vs Weekly Schedule of Cetuximab for First-Line Treatment of RAS Wild-Type Metastatic Colorectal Cancer
    Kasper-Virchow, Stefan
    Cheng, Ann-Lll
    Overkamp, Friedrich
    Rouyer, Magali
    Foch, Caroline
    Lamy, Francois-Xavier
    Esser, Regina
    Messinger, Diethelm
    Rothe, Vivien
    Chen, Wenfeng
    Brodowicz, Thomas
    Zielinski, Christoph
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 : 219 - 220
  • [2] Noninferiority of cetuximab every-2-weeks versus standard once-weekly administration schedule for the first-line treatment of RAS wild-type metastatic colorectal cancer
    Kasper, Stefan
    Foch, Caroline
    Messinger, Diethelm
    Esser, Regina
    Lamy, Francois-Xavier
    Rothe, Vivien
    Chen, Wenfeng
    Cheng, Ann-Lii
    Rouyer, Magali
    Brodowicz, Thomas
    Zielinski, Christoph
    EUROPEAN JOURNAL OF CANCER, 2021, 144 : 291 - 301
  • [3] Overall survival with cetuximab every-2-weeks versus standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumour location
    Kasper, Stefan
    Foch, Caroline
    Esser, Regina
    Zhang, Aimar
    Cheng, Ann-Lii
    Rouyer, Magali
    Brodowicz, Thomas
    Zielinski, Christoph
    EUROPEAN JOURNAL OF CANCER, 2023, 180 : 85 - 88
  • [4] Overall survival with cetuximab every 2 weeks vs standard once-weekly administration schedule for first-line treatment of RAS wild-type metastatic colorectal cancer in patients with left- and right-sided primary tumor location
    Kasper, S.
    Cheng, A.
    Rouyer, M.
    Foch, C.
    Lamy, F.
    Esser, R.
    Batech, M.
    Wong, C.
    Zhang, A.
    Brodowicz, T.
    Zielinski, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S114 - S114
  • [5] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Geoffrey Y. Ku
    Benjamin A. Haaland
    Gilberto de Lima Lopes
    Cancer Chemotherapy and Pharmacology, 2012, 70 : 231 - 238
  • [6] Cetuximab in the first-line treatment of K-ras wild-type metastatic colorectal cancer: the choice and schedule of fluoropyrimidine matters
    Ku, Geoffrey Y.
    Haaland, Benjamin A.
    Lopes, Gilberto de Lima, Jr.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2012, 70 (02) : 231 - 238
  • [7] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Tikhonova, Irina A.
    Huxley, Nicola
    Snowsill, Tristan
    Crathorne, Louise
    Varley-Campbell, Jo
    Napier, Mark
    Hoyle, Martin
    PHARMACOECONOMICS, 2018, 36 (07) : 837 - 851
  • [8] CETUXIMAB IN THE FIRST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER WITH LIVER-LIMITED DISEASE
    Souza, P., V
    Zanini, F. E.
    Biglia, L., V
    Kim, H. S.
    Fahham, L.
    VALUE IN HEALTH, 2017, 20 (09) : A875 - A875
  • [9] Economic Analysis of First-Line Treatment with Cetuximab or Panitumumab for RAS Wild-Type Metastatic Colorectal Cancer in England
    Irina A. Tikhonova
    Nicola Huxley
    Tristan Snowsill
    Louise Crathorne
    Jo Varley-Campbell
    Mark Napier
    Martin Hoyle
    PharmacoEconomics, 2018, 36 : 837 - 851
  • [10] Triplet chemotherapy plus cetuximab as first-line treatment in extended RAS wild-type metastatic colorectal cancer patients
    Samalin, Emmanuelle
    Mazard, Thibault
    Assenat, Eric
    Rouyer, Magali
    de la Fouchardiere, Christelle
    Guimbaud, Rosine
    Smith, Denis
    Portales, Fabienne
    Ychou, Marc
    Adenis, Antoine
    Fiess, Catherine
    Lopez-Crapez, Evelyne
    Thezenas, Simon
    DIGESTIVE AND LIVER DISEASE, 2024, 56 (08) : 1375 - 1381
12345